Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Effect of Bimagrumab on body composition: a systematic review and meta-analysis

Open access
Kanbay, Mehmet, Siriopol, Dimitrie, Copur, Sidar, Hasbal, Nuri Baris, Güldan, Mustafa, Kalantar-Zadeh, Kam, Garfias-Veitl, Tania, von Haehling, Stephan · 2024 · Aging Clinical and Experimental Research

Abstract

Background: Sarcopenia, a condition marked by progressive muscle mass and function decline, presents significant challenges in aging populations and those with chronic illnesses. Current standard treatments such as dietary interventions and exercise programs are often unsustainable. There is increasing interest in pharmacological interventions like bimagrumab, a monoclonal antibody that promotes muscle hypertrophy by inhibiting muscle atrophy ligands. Bimagrumab has shown effectiveness in various conditions, including sarcopenia. Aim: The primary objective of this meta-analysis is to evaluate the impact of bimagrumab treatment on both physical performance and body composition among patients diagnosed with sarcopenia. Materials and methods: This meta-analysis follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We systematically searched PubMed, Ovid/Medline, Web of Science, and the Cochrane Library databases up to June 2024 using appropriate Medical Subject Headings (MeSH) terms and keywords related to bimagrumab and sarcopenia. Eligible studies were randomized controlled trials (RCTs) that assessed the effects of bimagrumab on physical performance (e.g., muscle strength, gait speed, six-minute walk distance) and body composition (e.g., muscle volume, fat-free body mass, fat body mass) in patients with sarcopenia. Data extraction was independently performed by two reviewers using a standardized form, with discrepancies resolved through discussion or consultation with a third reviewer. Results: From an initial search yielding 46 records, we screened titles, abstracts, and full texts to include seven RCTs in our meta-analysis. Bimagrumab treatment significantly increased thigh muscle volume (mean difference [MD] 5.29%, 95% confidence interval [CI] 4.08% to 6.50%, P < 0.001; moderate heterogeneity χ2 = 6.41, I2 = 38%, P = 0.17) and fat-free body mass (MD 1.90 kg, 95% CI 1.57 kg to 2.23 kg, P < 0.001; moderate heterogeneity χ2 = 8.60, I2 = 30%, P = 0.20), while decreasing fat body mass compared to placebo (MD − 4.55 kg, 95% CI − 5.08 kg to − 4.01 kg, P < 0.001; substantial heterogeneity χ2 = 27.44, I2 = 89%, P < 0.001). However, no significant improvement was observed in muscle strength or physical performance measures such as gait speed and six-minute walk distance with bimagrumab treatment, except among participants with slower baseline walking speeds or distances. Discussion and conclusion: This meta-analysis provides valuable insights into the effects of bimagrumab on sarcopenic patients, highlighting its significant improvements in body composition parameters but limited impact on functional outcomes. The observed heterogeneity in outcomes across studies underscores the need for cautious interpretation, considering variations in study populations, treatment durations, and outcome assessments. While bimagrumab shows promise as a safe pharmacological intervention for enhancing muscle mass and reducing fat mass in sarcopenia, its minimal effects on muscle strength and broader physical performance suggest potential limitations in translating body composition improvements into functional gains. Further research is needed to clarify its long-term efficacy, optimal dosing regimens, and potential benefits for specific subgroups of sarcopenic patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40520-024-02825-4

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Flow diagram of the study selection process
Fig. 1 Flow diagram of the study selection processCC BY · PubMed Central
Fig. 2 Forest plot of the included studies for the effect of bimagrumab on thigh muscle volume, fat-free body mass and fat body mass
Fig. 2 Forest plot of the included studies for the effect of bimagrumab on thigh muscle volume, fat-free body mass and fat body massCC BY · PubMed Central
Fig. 3 Funnel plot of the mean differences in thigh muscle volume, lean body mass and fat body mass versus standard errors of the mean differences The x-axis is in % (for thigh muscle volume) or Kg (for lean body mass and fat body mass)
Fig. 3 Funnel plot of the mean differences in thigh muscle volume, lean body mass and fat body mass versus standard errors of the mean differences The x-axis is in % (for thigh muscle volume) or Kg (for lean body mass and fat body mass)CC BY · PubMed Central
Fig. 4 Cellular Signal Targets and Metabolic Effects of anti-Activin Type 2 Receptor Antibody Bimagrumab
Fig. 4 Cellular Signal Targets and Metabolic Effects of anti-Activin Type 2 Receptor Antibody BimagrumabCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

See all 58

Metadata

Authors
Kanbay, M., Siriopol, D., Copur, S., Hasbal, N. B., Güldan, M., Kalantar-Zadeh, K., Garfias-Veitl, T., & von Haehling, S.
Affiliations
  • Koç University (TR)
  • Ştefan cel Mare University of Suceava (RO)
Venue
Aging Clinical and Experimental Research
Published
2024-09-09
Volume
36
Issue
1
Pages
185-185
ISSN
  • 1594-0667 (ISSN-L)
  • 1720-8319
OpenAlex
W4402349387
Cited by
45
References
35
Citations by year
2026: 21 · 2025: 23 · 2024: 1
FWCI
2.56
Type
journal article
Language
en
Open access
Licence
Locations
  • Aging Clinical and Experimental Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PUBLISSO (German National Library of Medicine) (submittedVersion, cc-by)
  • GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
Funders
Herzzentrum Göttingen
Topics
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
  • Health Sciences › Nursing › Nutrition and Dietetics › Muscle metabolism and nutrition
Keywords
bimagrumab, sarcopenia, body composition, muscle hypertrophy, thigh muscle volume, fat-free mass, fat mass, physical performance, muscle strength, walking speed, 6-minute walk distance, monoclonal antibodies, aging, chronic disease, adverse events, cost-effectiveness, quality of life
MeSH terms
Body Composition, Humans, Randomized Controlled Trials as Topic, Muscle Strength, Sarcopenia, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Bimagrumab on body composition: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1007/s40520-024-02825-4
The paper
Kanbay, M., Siriopol, D., Copur, S., Hasbal, N. B., Güldan, M., Kalantar-Zadeh, K., Garfias-Veitl, T., & von Haehling, S. (2024). Effect of Bimagrumab on body composition: a systematic review and meta-analysis. Aging Clinical and Experimental Research. https://doi.org/10.1007/s40520-024-02825-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.